A new treatment approach for advanced prostate cancer using specialized nanoparticles
A Multimodal Hierarchical Theranostic Nanoparticle for Castration Resistant Prostate Cancer
This study is testing a new type of tiny particle that can help deliver cancer treatment directly to tumors in men with advanced prostate cancer, aiming to make the treatment work better and cause fewer side effects.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Western New York Healthcare System NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11098533 on NIH RePORTER |
What this research studies
This research focuses on developing a novel theranostic nanoparticle designed to target and treat castration-resistant prostate cancer (CRPC). The approach aims to enhance drug delivery directly to the tumor site while reducing side effects associated with systemic treatments. By utilizing advanced technology, the study seeks to improve the effectiveness of existing therapies and provide better outcomes for patients with advanced stages of prostate cancer. Patients may be monitored for their response to this innovative treatment over the course of the research.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer, particularly those who have undergone androgen deprivation therapy.
Not a fit: Patients with early-stage prostate cancer or those who do not have castration-resistant prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for advanced prostate cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While innovative nanoparticle therapies are being explored, this specific approach targeting CRPC is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Buffalo, United States
- VA Western New York Healthcare System — Buffalo, United States (Active)
Researchers
- Principal investigator: Schwartz, Stanley a — VA Western New York Healthcare System
- Study coordinator: Schwartz, Stanley a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.